Comparative efficacy and safety of donafenib versus bevacizumab in combination with immune checkpoint inhibitors and interventional therapy for advanced hepatocellular carcinoma: A retrospective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results